Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 5 years old and ≤17 years old~* OAB diagnostic according to the International Children Continence Society (ICCS) and less than 65% of the expected mean bladder capacity for age is confirmed (30 + (age in years x 30) mL) on a 3-day voiding diary.~* Weight and height are within the normal percentile (3rd to 97th percentile) and weight is ≥ 20 kg (3rd percentile of a 8 y.o. child, boy or girl), according to the CDC growth chart~* Ability to swallow pills~* Subjects/parents (vs. legal guardian) agree to participate to the following study and sign the informed consent~* Subjects/parents (vs. legal guardian) are able to comply with the study requirements and with the medication restrictions.~* Female subjects of childbearing potential must have a negative serum or urine pregnancy test at enrollment and must agree to maintain highly effective birth control during the study. Sexually active male subjects agree to use a barrier method of birth control with female partner for the duration of the study and at least one month after ending study treatment. Sexually active male subjects agree to use a condom for the duration of the study and for at least one month after ending study treatment and the female partner to use a reliable form of birth control for the duration of the study and for at least one month after ending study treatment.~* Patients without symptom improvement or with partial response under medical therapy (at least 2 different antimuscarinic agents) or with significantly bothersome S/E on antimuscarinics.~Exclusion Criteria:~* Subject has a diagnostic of dysfunctional voiding~* Post-voiding residue \> 20 cc~* Polyuria (\> 75 ml/kg/b.w./24 hours)~* Nephrogenic of central diabetes insipidus~* Constipation at screening (if the patient is treated and the treatment is successful, the patient will be eligible to the study)~* Urinary tract infection at visit 2-3-4. If UTI is present at the screening visit, the UTI must be treated and the success of the treatment must be documented with a negative urinalysis at visit 2.~* QTc interval greater than 460 ms, or any increase of 30 ms on follow-up EKG (mean of 6 separate EKG-3 from visit week-2 and 3 from visit week 0). If a patient meets those criteria in the first month (initial dose), he will be excluded from the study. If the QTc change is noted after the up-titration, the dose will be decreased and EKG will be repeated within 1 week to ensure normalization of QTc.~* Clinically significant unstable medical condition or disorder~* Subject is pregnant or intends to become pregnant~* Serum creatinin more than or equal to 2 times the upper limit of normal~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than or equal to 2 times ULN, or bilirubin more than or equal to 1.5 times ULN.~* Known hypersensitivity to mirabegron or any contraindication to the use of the molecule, in accordance to the product monography (to the exception of pediatric age).~* Subject is taking medication that interact with mirabegron and this medication can't be discontinued (see appendix 1 of excluded drugs)~* Known urological pathology other than OAB that could explain urinary symptoms (as bladder stone...)~* Non-treated or non-controlled arterial hypertension

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Mirabegron (Type: EXPERIMENTAL): Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.

Based on this trial design, predict the completion outcome and termination type (if applicable).